Prominent belgian professor. He retired as an Emeritus Professor in 2013 but he is still involved in teaching and consultancy activities for universities and hospitals. His research interests include multivariate logistic regression, survival analysis, clinical decision-making, quality control and epidemiology. He acquired a wide experience in the development and application of statistical methods in medicine and biomedical sciences. Author or co-author of over 600 international scientific articles in the field of biostatistics and medical computing in prestigious journals.

Ahmad Awada is Head of the Oncology Medicine Department at Jules Bordet Cancer Institute Brussels, Belgium. He did a specialization in Internal Medicine and Medical Oncology at Jules Bordet Institute, in Brussels, until 1992. He stayed in the Netherlands (New Drug Development Office, Free University, Amsterdam) and in San Antonio, USA (Institute for Drug Development). He focused on the clinical development of new anticancer agents. He has an important clinical activity in the treatment of solid tumors and in particular breast cancer. Dr Awada took an active part in the development of new drugs (cytotoxics, molecular-targeted therapies, immunotherapy), some of them already widely used. Dr Awada is member of several international scientific societies (ASCO, EORTC, ESMO) and Professor of Clinical Medicine and Medical Oncology at the Université Libre de Brussels. He has published 28 book chapters and 314 peer-reviewed articles in international publications.

María del Carmen Cabezas MD., PhD, did her specialty studies and PhD at the University of Liège-Belgium (ULg), with a training in Epidemiology at the Erasmus University (Rotterdam-The Netherlands), and Problem Based Learning at Maastricht University, is General Manager of Health & Research Services, main professor in the Faculty of Medicine of the Pontifical Catholic University of Ecuador. At the publication level, she is board member of Science Direct Group and the International Journal of HIV/AIDS Prevention, peer reviewer of several international journals with a high impact factor such as AIDS & Behavior, Peer J, among others. Researcher and Coordinator of clinical studies of phase I-IV, epidemiological, pharma-economic and public health researchs. She has several publications in international journals as main author and co-author in epidemiology, public health, and pharma-economic topics. Her main interest is the development of international education programs with European and Canadian organizations in support of the education system in Latin America.

Principal Investigator of National Fund for Scientific Research (FNRS), head of the Laboratory of Cancer Signaling Group of Applied Genoproteomics (GIGA) and professor at the University of Liège (ULg), Belgium. He has had a great interest in new mechanisms promoting tumor adaptation to identify novel therapeutic strategies in the treatment of invasive or resistant human cancers. Author and co-author of many international scientific publications in high impact factor journals such as: Nature, Cell, Oncogene, Journal of Biological Chemistry among others.

Head of medical oncology and head of the laboratory of molecular oncology at the Hospital of Free University of Brussels (ULB), Belgium, editor in chief of the Belgian journal of medical oncology, chairman of the Belgian working party for the development of national cancer guidelines. He is professor of medical oncology and coordinator of a course “Molecular Targets in Cancer” at the ULB, Belgium, as well as coordinator of a national interuniversity postgraduate course in medical oncology. He has a special interest in genomic-driven translational therapeutic studies. He has more than 150 international scientific publications in high impact factor journals.

Associate Professor at University of Antwerp (Belgium) from August 2014, Associate Professor at KU Leuven (Belgium) from August 2013 and staff member at Iridium Cancer Network (Antwerp, Belgium) from May 2014. He obtained his PhD in medical sciences (KU Leuven, Belgium) and a specialist in radiation oncology (KU Leuven, Belgium). Professor in international ESTRO courses. Editorial board member: Belgian Journal of Medical Oncology (BJMO) and World Journal of Radiology (WJR). Author and co-author of several publications in prestigious journals. During 2021 he acted as sub investigator with relevant trials such as Oligorecurrent Prostate Cancer and Radiation oncology. Recently, he had the training ICH GCP in this current 2022.

Oncology Specialist. Physician in the clinical oncology department of the University Hospital Center (CHU) of Liège, Belgium. In 2018 he finished his PhD at the Interdisciplinary Cluster Research Center for Applied Genoproteomics (GIGA) in Liège, Belgium, his thesis topic was “The role of circulating microRNA in breast cancer”. He has 21 international publications in oncology as author and co-author.

Head of clinics at University Hospital Center (CHU) of Liège, Belgium and researcher of clinical trials. She is currently involved in the daily clinical management of patients with solid tumors, focusing particularly on genitourinary, gynecological, sarcoma and rare tumors. Also, she is local Principal Investigator and sub-investigator at CHU of Liège, Belgium Trials research Unit, Medical Oncology Department. She has more than 30 scientific publications as author and coauthor.

Enrique Grande, MD., Msc., PhD., Director of the Medical Oncology Program and Clinical Research lead at the MD Anderson Madrid International Cancer Center. He is focus on the research on Genitourinary and Endocrine tumors and takes active collaboration in the development of the Translational Research and Early Drug Development Unit. He was awarded his PhD for a pharmacokinetic and pharmacodynamic study of tyrosine kinase inhibitors in liver metabolism, and he holds a master’s degree in the molecular biology of cancer from the Spanish National Cancer Research Centre (CNIO). He has published as author more than 150 manuscripts in peer-reviewed journals, Dr Grande is also the founder of the Spanish group for research on orphan and uncommon tumors (GETHI). Professor at the Francisco de Vitoria University, editor of several international journals. He has participated in the most recent trials in the field of RCC that led to the approval of the new drugs we have now available.

PhD in biomedical and pharmaceutical sciences. Scientific collaborator in Telelife, Belgian National Fund for Scientific Research (FNRS), University of Liège (ULg). He completed his post-doctorate in the laboratory of Professor Christopher Crum at Harvard University (Brigham and Women's Hospital, Boston). Since 2006, his interest has focused on microenvironment/origin and HPV tumors. He has more than 40 international publications in high impact factor journals.

Medical Oncologist at the Centre Hospitalier in Luxemburg. Her main work experience is: Clinical research, early clinical trials, involved in conducting and manage the phase I clinical studies, with pharmaceutical companies at Cliniques Universitaires Saint-Luc, Brussels, Prof J-P Machiels. Dr. Herremans has a specialization in Internal Medicine focused on Hematology and Medical Oncology in palliative care at the State Medical Chamber of Baden-Württemberg in Germany.

Doctor in medicine and specialist in Medical Oncology. He is currently head of the Medical Oncology Service at the Arnau de Vilanova Hospital in Valencia and full professor of Clinical Oncology at the Catholic University of Valencia, Spain. With more than 5 years of academic training and research in France and the United States, he is an international expert in breast cancer, with more than 90 indexed publications in the last 5 years. Involved in different Breast Cancer research groups, he is a founding partner and senior-expert at MedSIR (2012), a company dedicated to promoting high-impact clinical research in collaboration with the scientific community, pharmaceutical and biotech companies.

Agnès Noël M.Sc., PhD Recognized Belgian researcher. Director of the research center Interdisciplinary Cluster in Applied Genoproteomics (GIGA)-cancer. President of the thematic graduate school in experimental cancerology of the National Fund for Research (FNRS) of Belgium. Professor of molecular cell biology and molecular oncology and president of the council of research and valorization in health sciences at the University of Liege (ULg). Author and co-author of more than 160 international scientific articles.

She currently works as a medical oncologist at the IRCCS “Regina Elena” National Cancer Institute in Rome, Italy. Specialized in Oncology at the University of Rome Sapienza in Italy. She holds a Doctorate in Biomedical and Pharmaceutical Sciences from the University of Liege in Belgium. Experience in Medical Oncology, in management of Clinical Trials as Sub-Investigator, in translational and fundamental research in cancer. Author and co-author of more than fifty articles and summaries. She has carried out preclinical research at the Gustave Roussy Cancer Institute, INSERM Unit U981, Villejuif, France. From 2017 to 2021 she was oncologist at the CHU in Liège, Belgium.

Marc Peeters is Professor of oncology and CEO at the Antwerp University, Belgium. He is head of the oncology department at the Antwerp University Hospital and coordinator of the Multidisciplinary Oncology Center Antwerp. He is also chairman of the College of Oncology. Previously, he was Coordinator of the Digestive Oncology Unit at the University Hospital in Ghent, Belgium. He completed his medical studies at the Catholic University in Leuven, Belgium. He underwent additional training in Oncology and Digestive Oncology at the UZ Gasthuisberg, the Institut Gustave Roussy in Villejuif, Paris, the University of Pennsylvania Hospital in Philadelphia, the Royal Marsden Hospital in London, and the Memorial Sloan-Kettering Cancer Center in New York.

Head and professor of clinics at the department of oncology, local Principal Investigator, and sub-investigator at University Hospital Center (CHU) of Liège, researcher of clinical trials of phase I-IV. He is currently involved in the daily clinical management of patients with solid tumors with interest in those of the urinary tract and head and neck. He has more than 40 international scientific publications as author and co-author.